162 related articles for article (PubMed ID: 16917869)
1. Novel colon-specific microspheres with highly dispersed hydroxycamptothecin cores: their preparation, release behavior, and therapeutic efficiency against colonic cancer.
Lu B; Zhang Z
J Pharm Sci; 2006 Dec; 95(12):2619-30. PubMed ID: 16917869
[TBL] [Abstract][Full Text] [Related]
2. Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect.
Wang A; Li S
BMC Biotechnol; 2008 May; 8():46. PubMed ID: 18454874
[TBL] [Abstract][Full Text] [Related]
3. Sustained release of hydroxycamptothecin after subcutaneous administration using a novel phospholipid complex-DepoFoam technology.
Zhao Y; Liu J; Sun X; Zhang ZR; Gong T
Drug Dev Ind Pharm; 2010 Jul; 36(7):823-31. PubMed ID: 20515403
[TBL] [Abstract][Full Text] [Related]
4. Preparation, characterization, biodistribution and antitumor efficacy of hydroxycamptothecin nanosuspensions.
Han M; Liu X; Guo Y; Wang Y; Wang X
Int J Pharm; 2013 Oct; 455(1-2):85-92. PubMed ID: 23928147
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanoparticles loaded with 10-hydroxycamptothecin-phospholipid complex developed for the treatment of hepatoma in clinical application.
Wei W; Shi SJ; Liu J; Sun X; Ren K; Zhao D; Zhang XN; Zhang ZR; Gong T
J Drug Target; 2010 Aug; 18(7):557-66. PubMed ID: 20131981
[TBL] [Abstract][Full Text] [Related]
6. Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer.
Ping YH; Lee HC; Lee JY; Wu PH; Ho LK; Chi CW; Lu MF; Wang JJ
Oncol Rep; 2006 May; 15(5):1273-9. PubMed ID: 16596197
[TBL] [Abstract][Full Text] [Related]
7. Intracellular target delivery of 10-hydroxycamptothecin with solid lipid nanoparticles against multidrug resistance.
Liu M; Chen D; Wang C; Chen X; Wen Z; Cao Y; He H
J Drug Target; 2015; 23(9):800-5. PubMed ID: 25766079
[TBL] [Abstract][Full Text] [Related]
8. Novel pH-sensitive lipid-polymer composite microspheres of 10-hydroxycamptothecin exhibiting colon-specific biodistribution and reduced systemic absorption.
Gan L; Gao YP; Zhu CL; Zhang XX; Gan Y
J Pharm Sci; 2013 Jun; 102(6):1752-1759. PubMed ID: 23605625
[TBL] [Abstract][Full Text] [Related]
9. 10-Hydroxycamptothecin (HCPT) nanosuspensions stabilized by mPEG
Yang L; Hong J; Di J; Guo Y; Han M; Liu M; Wang X
Int J Nanomedicine; 2017; 12():3681-3695. PubMed ID: 28553107
[TBL] [Abstract][Full Text] [Related]
10. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
[TBL] [Abstract][Full Text] [Related]
11. Effect of alkyl chain on cellular uptake and antitumor activity of hydroxycamptothecin nanoparticles based on amphiphilic linear molecules.
Guo Y; Wang T; Zhao S; Qiu H; Han M; Dong Z; Wang X
Eur J Pharm Sci; 2018 Nov; 124():266-272. PubMed ID: 30189259
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyethyl starch conjugates for improving the stability, pharmacokinetic behavior and antitumor activity of 10-hydroxy camptothecin.
Li G; Li Y; Tang Y; Zhang Y; Zhang Y; Yin T; Xu H; Cai C; Tang X
Int J Pharm; 2014 Aug; 471(1-2):234-44. PubMed ID: 24861941
[TBL] [Abstract][Full Text] [Related]
13. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance.
Liu M; Chen D; Mukerabigwi JF; Chen S; Zhang Y; Lei S; Luo S; Wen Z; Cao Y; Huang X; He H
J Drug Target; 2016; 24(5):433-40. PubMed ID: 26422582
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumor targeting and antitumor efficacy via hydroxycamptothecin-encapsulated folate-modified N-succinyl-N'-octyl chitosan micelles.
Zhu H; Cao J; Cui S; Qian Z; Gu Y
J Pharm Sci; 2013 Apr; 102(4):1318-32. PubMed ID: 23400693
[TBL] [Abstract][Full Text] [Related]
15. Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α.
Qi Y; Liu G
Drug Deliv; 2021 Dec; 28(1):171-182. PubMed ID: 33427515
[TBL] [Abstract][Full Text] [Related]
16. [Preparation of PEG-modified nanostructured lipid carriers loaded with hydroxycamptothecin and tissue distribution in mice].
Zhang XX; Gan Y; Yang XG; Zhu CL; Gan L; Nie SF; Pan WS
Yao Xue Xue Bao; 2008 Jan; 43(1):91-6. PubMed ID: 18357740
[TBL] [Abstract][Full Text] [Related]
17. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity.
Shi B; Fang C; Pei Y
J Pharm Sci; 2006 Sep; 95(9):1873-87. PubMed ID: 16795003
[TBL] [Abstract][Full Text] [Related]
18. Enhanced oral bioavailability of 10-hydroxycamptothecin through the use of poly (n-butyl cyanoacrylate) nanospheres.
Jin X; Asghar S; Zhu X; Chen Z; Liu J; Li Y; Li H; Ping Q; Xiao Y
Drug Dev Ind Pharm; 2017 Oct; 43(10):1637-1647. PubMed ID: 28481657
[TBL] [Abstract][Full Text] [Related]
19. A stabilizer-free and organic solvent-free method to prepare 10-hydroxycamptothecin nanocrystals: in vitro and in vivo evaluation.
Yang X; Liu Y; Zhao Y; Han M; Guo Y; Kuang H; Wang X
Int J Nanomedicine; 2016; 11():2979-94. PubMed ID: 27382284
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate.
Wang Y; Li L; Jiang W; Larrick JW
Bioorg Med Chem; 2005 Oct; 13(19):5592-9. PubMed ID: 16084097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
